These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 38784143)

  • 21. Training family members to manage heroin overdose and administer naloxone: randomized trial of effects on knowledge and attitudes.
    Williams AV; Marsden J; Strang J
    Addiction; 2014 Feb; 109(2):250-9. PubMed ID: 24103087
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "It can save your life, that's all I know," barriers and facilitators for engagement in take-home naloxone for people receiving opioid substitution treatment in regional Australia: An explorative study.
    Natale I; Harvey C; Wood P; Anderson K
    Qual Res Med Healthc; 2023 Jul; 7(2):10868. PubMed ID: 37692452
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Factors associated with take-home naloxone kit usage in British Columbia: an analysis of administrative data.
    Lei V; Ferguson M; Geiger R; Williams S; Liu L; Buxton JA
    Subst Abuse Treat Prev Policy; 2022 Mar; 17(1):25. PubMed ID: 35361228
    [TBL] [Abstract][Full Text] [Related]  

  • 24. "Naloxone? Not for me!" First cross-assessment by patients and healthcare professionals of the risk of opioid overdose.
    Aquizerate A; Rousselet M; Cochard A; Guerlais M; Gerardin M; Lefebvre E; Duval M; Laforgue EJ; Victorri-Vigneau C
    Harm Reduct J; 2024 Jan; 21(1):20. PubMed ID: 38263159
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Take-home naloxone possession among people who inject drugs in rural West Virginia.
    Allen ST; White RH; O'Rourke A; Grieb SM; Kilkenny ME; Sherman SG
    Drug Alcohol Depend; 2019 Nov; 204():107581. PubMed ID: 31574407
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An overview of take-home naloxone programs in Australia.
    Dwyer R; Olsen A; Fowlie C; Gough C; van Beek I; Jauncey M; Lintzeris N; Oh G; Dicka J; Fry CL; Hayllar J; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):440-449. PubMed ID: 29744980
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Risks and overdose responses: Participant characteristics from the first seven years of a national take-home naloxone program.
    Ericson ØB; Eide D; Lobmaier P; Clausen T
    Drug Alcohol Depend; 2022 Nov; 240():109645. PubMed ID: 36191532
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Acceptability of prison-based take-home naloxone programmes among a cohort of incarcerated men with a history of regular injecting drug use.
    Curtis M; Dietze P; Aitken C; Kirwan A; Kinner SA; Butler T; Stoové M
    Harm Reduct J; 2018 Sep; 15(1):48. PubMed ID: 30241532
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Injection Drug Use Frequency Before and After Take-Home Naloxone Training.
    Colledge-Frisby S; Rathnayake K; Nielsen S; Stoove M; Maher L; Agius PA; Higgs P; Dietze P
    JAMA Netw Open; 2023 Aug; 6(8):e2327319. PubMed ID: 37540514
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of patterns of opioid overdose and interventions delivered at a tertiary hospital emergency department: impact of COVID-19.
    Potaka KL; Freeman R; Soo D; Nguyen NA; Sim TF; Moullin JC
    BMC Emerg Med; 2022 Apr; 22(1):62. PubMed ID: 35397487
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Does training people to administer take-home naloxone increase their knowledge? Evidence from Australian programs.
    Dietze PM; Draper B; Olsen A; Chronister KJ; van Beek I; Lintzeris N; Dwyer R; Nelson M; Lenton S
    Drug Alcohol Rev; 2018 May; 37(4):472-479. PubMed ID: 29473245
    [TBL] [Abstract][Full Text] [Related]  

  • 32. With crisis comes opportunity: Unanticipated benefits resulting from pivots to take-home naloxone (THN) programs during the COVID-19 pandemic.
    Courser MW; Raffle H
    J Subst Abuse Treat; 2021 Mar; 122():108220. PubMed ID: 33309390
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Preventing opioid overdose with peer-administered naloxone: findings from a rural state.
    Hanson BL; Porter RR; Zöld AL; Terhorst-Miller H
    Harm Reduct J; 2020 Jan; 17(1):4. PubMed ID: 31918740
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Guidance on take-home naloxone distribution and use by community overdose responders in Canada.
    Ferguson M; Rittenbach K; Leece P; Adams A; Ali F; Elton-Marshall T; Burmeister C; Brothers TD; Medley A; Choisil P; Strike C; Ng J; Lorenzetti DL; Gallant K; Buxton JA;
    CMAJ; 2023 Aug; 195(33):E1112-E1123. PubMed ID: 37640401
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Preventing deaths from rising opioid overdose in the US - the promise of naloxone antidote in community-based naloxone take-home programs.
    Straus MM; Ghitza UE; Tai B
    Subst Abuse Rehabil; 2013 Sep; 2013(4):65-72. PubMed ID: 24273417
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Rethinking 'carriage' of take-home naloxone.
    McDonald R; Parkin S; Eide D; Neale J; Clausen T; Metrebian N; Carter B; Strang J
    Int J Drug Policy; 2021 Sep; 95():103253. PubMed ID: 33848942
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Distribution of take-home opioid antagonist kits during a synthetic opioid epidemic in British Columbia, Canada: a modelling study.
    Irvine MA; Buxton JA; Otterstatter M; Balshaw R; Gustafson R; Tyndall M; Kendall P; Kerr T; Gilbert M; Coombs D
    Lancet Public Health; 2018 May; 3(5):e218-e225. PubMed ID: 29678561
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Opioid-overdose laws association with opioid use and overdose mortality.
    McClellan C; Lambdin BH; Ali MM; Mutter R; Davis CS; Wheeler E; Pemberton M; Kral AH
    Addict Behav; 2018 Nov; 86():90-95. PubMed ID: 29610001
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Take-Home Naloxone Kits: Attitudes and Likelihood-Of-Use Outcomes from a European Survey of Potential Overdose Witnesses.
    McDonald R; Breidahl S; Abel-Ollo K; Akhtar S; Clausen T; Day E; Kelleher M; McAuley A; Petersen H; Sefranek M; Thiesen H; Strang J
    Eur Addict Res; 2022; 28(3):220-225. PubMed ID: 35114666
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Implementing take-home naloxone in an urban community pharmacy.
    Akers JL; Hansen RN; Oftebro RD
    J Am Pharm Assoc (2003); 2017; 57(2S):S161-S167. PubMed ID: 28202384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.